Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.

M ArgyropoulouT KanniM KyprianouN MelachroinopoulosEvangelos J Giamarellos-Bourboulis

Published in: The British journal of dermatology (2018)

Treatment with anti-TNF agents achieves significant cost-benefit through containment of HS exacerbations. The efficacy of anti-TNF agents was similar for both disease stages.

Keyphrases

systemic lupus erythematosus
hidradenitis suppurativa
rheumatoid arthritis
chronic obstructive pulmonary disease
cystic fibrosis
juvenile idiopathic arthritis
ulcerative colitis
smoking cessation